{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T06:17:41Z","timestamp":1789107461769,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bneo.2025.100179","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:01:51Z","timestamp":1762596111000},"page":"100179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-3263","authenticated-orcid":false,"given":"Chad C.","family":"Bjorklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Larrayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiling","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Shtraizent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4215-4884","authenticated-orcid":false,"given":"Chih-Chao","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amatangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1690-8035","authenticated-orcid":false,"given":"Tracy T.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Wollerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Sridhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Dudhgaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Subramanyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-1706","authenticated-orcid":false,"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-1625","authenticated-orcid":false,"given":"Anita K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib1","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2021-147812","volume":"138","author":"Richardson","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100179_bib2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bneo.2025.100179_bib3","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-021-01514-0","article-title":"Evolution of treatment paradigms in newly diagnosed multiple myeloma","volume":"81","author":"Elnair","year":"2021","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.bneo.2025.100179_bib4","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib5","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1182\/blood-2019-124338","article-title":"CC-92480 is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunomodulatory activity against sensitive and resistant multiple myeloma cells","volume":"134","author":"Lopez-Girona","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100179_bib6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10272","key":"10.1016\/j.bneo.2025.100179_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"The Lancet"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a novel cereblon E3 ligase modulator, is synergistic with dexamethasone, bortezomib, and daratumumab in multiple myeloma","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100179_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.bneo.2025.100179_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood-2017-05-782961","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma","volume":"130","author":"Paludo","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100179_bib11","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib12","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2018-99-118829","article-title":"Mechanistic insights of pomalidomide activity in combination with bortezomib and dexamethasone in multiple myeloma and immune cells","volume":"132","author":"Katz","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100179_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjh.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bneo.2025.100179_bib14","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S2152-2650(22)00560-2","article-title":"P-230: preclinical and translational biomarker analysis to support further clinical development and dose optimization of mezigdomide (MEZI; CC-92480) in combination with either bortezomib or carfilzomib","volume":"22","author":"Amatangelo","year":"2022","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood-2021-153994","article-title":"Pre-clinical and clinical immunomodulatory effects of pomalidomide or CC-92480 in combination with bortezomib in multiple myeloma","volume":"138","author":"Bjorklund","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib16","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2021-153907","article-title":"CC-92480 enhances cell-autonomous cytotoxicity through blockade of G 2\/M transition when combined with bortezomib\/dexamethasone in pre-clinical multiple myeloma","volume":"138","author":"Bjorklund","year":"2021","journal-title":"Blood"},{"issue":"5971","key":"10.1016\/j.bneo.2025.100179_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bneo.2025.100179_bib18","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.bneo.2025.100179_bib19","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100179_bib20","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6168","key":"10.1016\/j.bneo.2025.100179_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6619","key":"10.1016\/j.bneo.2025.100179_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bneo.2025.100179_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.bneo.2025.100179_bib24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10 years later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100179_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2567.2007.02761.x","article-title":"Proteasome inhibition suppresses essential immune functions of human CD4+ T cells","volume":"124","author":"Berges","year":"2008","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.bneo.2025.100179_bib26","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100179_bib27","first-page":"e315","article-title":"Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma","volume":"100","author":"Shi","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bneo.2025.100179_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jcph.1602","article-title":"Population pharmacokinetics and exposure response analysis of pomalidomide in subjects with relapsed or refractory multiple myeloma from the novel combination treatment of pomalidomide, bortezomib, and low-dose dexamethasone","volume":"60","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"14 suppl 11","key":"10.1016\/j.bneo.2025.100179_bib29","first-page":"14","article-title":"Pharmacology, pharmacokinetics, and practical applications of bortezomib","volume":"18","author":"Schwartz","year":"2004","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.bneo.2025.100179_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056132","article-title":"Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib","volume":"8","author":"Shabaneh","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bneo.2025.100179_bib31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chembiol.2018.11.007","article-title":"Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors","volume":"26","author":"Besse","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100179_bib32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100179_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.bneo.2025.100179_bib34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bneo.2025.100179_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11095-019-2570-2","article-title":"A theoretical model for the cell cycle and drug induced cell cycle arrest of FUCCI systems with cell-to-cell variation during mitosis","volume":"36","author":"Bae","year":"2019","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.bneo.2025.100179_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13046-020-01597-9","article-title":"A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe","volume":"39","author":"Hu","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100179_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.bneo.2025.100179_bib38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100179_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CAD.0000000000001041","article-title":"The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma","volume":"32","author":"Wang","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"12","key":"10.1016\/j.bneo.2025.100179_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40262-012-0010-0","article-title":"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma","volume":"51","author":"Moreau","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.bneo.2025.100179_bib41","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100179_bib42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100179_bib43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"6414","key":"10.1016\/j.bneo.2025.100179_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bneo.2025.100179_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.apsb.2016.06.002","article-title":"The Ikaros family of zinc-finger proteins","volume":"6","author":"Fan","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100179_bib46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2023-189445","article-title":"Mezigdomide reverses T-cell exhaustion through degradation of Aiolos\/Ikaros and reinvigoration of cytokine production pathways","volume":"142","author":"Chiu","year":"2023","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:48:59Z","timestamp":1771465739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2950328025001141"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100179","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100179"}}